These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37463054)

  • 1. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
    Anders HJ; Furie R; Malvar A; Zhao MH; Hiromura K; Weinmann-Menke J; Green Y; Jones-Leone A; Negrini D; Levy RA; Lightstone L; Tanaka Y; Rovin BH
    Nephrol Dial Transplant; 2023 Nov; 38(12):2733-2742. PubMed ID: 37463054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
    Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
    N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH; Furie R; Teng YKO; Contreras G; Malvar A; Yu X; Ji B; Green Y; Gonzalez-Rivera T; Bass D; Gilbride J; Tang CH; Roth DA
    Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K; Kurita N; Noma H; Matsuki T; Quasny H; Levy RA; Jones-Leone AR; Gairy K; Yajima N
    Lupus Sci Med; 2022 Sep; 9(1):. PubMed ID: 37017254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
    Malvar A; Alberton V; Recalde C; Heguilen R
    Lupus; 2023 Oct; 32(12):1394-1401. PubMed ID: 37754750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
    J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.
    Simeoni M; Yang S; Tompson DJ; Dimelow R
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):289-301. PubMed ID: 38551711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
    Gomez A; Jägerback S; Sjöwall C; Parodis I
    Rheumatology (Oxford); 2024 Feb; 63(2):338-348. PubMed ID: 37228028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.
    Dimelow R; Liefaard L; Green Y; Tomlinson R
    Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H; Chen C; Yang H; Tu J
    Eur J Pediatr; 2024 Sep; 183(9):3987-3995. PubMed ID: 38940925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.